Eyegate Pharmaceuticals Inc (EYEG) Shares Gap Up to $2.46
Shares of Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) gapped up before the market opened on Monday . The stock had previously closed at $2.43, but opened at $2.46. Eyegate Pharmaceuticals shares last traded at $2.50, with a volume of 13,284 shares changing hands.
A number of brokerages have commented on EYEG. Maxim Group reaffirmed a “buy” rating and set a $10.00 price target on shares of Eyegate Pharmaceuticals in a research report on Thursday, June 2nd. Chardan Capital reaffirmed a “buy” rating on shares of Eyegate Pharmaceuticals in a research report on Thursday, April 14th. Rodman & Renshaw reaffirmed a “buy” rating on shares of Eyegate Pharmaceuticals in a research report on Monday, June 13th. Finally, Noble Financial began coverage on shares of Eyegate Pharmaceuticals in a research report on Thursday, April 7th. They set a “buy” rating and a $10.00 price target on the stock. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Eyegate Pharmaceuticals has an average rating of “Buy” and an average price target of $9.00.
The company’s market cap is $20.03 million. The firm’s 50-day moving average is $2.76 and its 200 day moving average is $2.99.
In related news, major shareholder Ventech Capital Ii sold 29,400 shares of the company’s stock in a transaction on Wednesday, June 8th. The shares were sold at an average price of $3.25, for a total transaction of $95,550.00. Following the sale, the insider now owns 1,641,540 shares of the company’s stock, valued at $5,335,005. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Morton Goldberg sold 15,000 shares of the company’s stock in a transaction on Wednesday, June 15th. The shares were sold at an average price of $3.16, for a total transaction of $47,400.00. Following the sale, the director now directly owns 17,277 shares in the company, valued at approximately $54,595.32. The disclosure for this sale can be found here.
Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.